Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. - Wikidata - wikimedia - TriplyDB

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

http://www.wikidata.org/entity/Q30419997

about

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases Cellular senescence in aging and age-related disease: from mechanisms to therapy Optimal management of hormone receptor positive metastatic breast cancer in 2016 The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis RB1: a prototype tumor suppressor and an enigma Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex Emerging therapies for breast cancer Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions Palbociclib: an evidence-based review of its potential in the treatment of breast cancer The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.The history and future of targeting cyclin-dependent kinases in cancer therapy.ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer Molecular characterization and targeted therapeutic approaches in breast cancer The Role of CDK4/6 Inhibition in Breast Cancer.RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer.Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.Modification of the DNA damage response by therapeutic CDK4/6 inhibition.Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors Regulation of miR106b cluster through the RB pathway: mechanism and functional targets.Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)Targeting cell cycle and hormone receptor pathways in cancer.Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer.Progress with palbociclib in breast cancer: latest evidence and clinical considerations.Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.Cell cycle proteins as promising targets in cancer therapy The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.Emerging strategies to overcome resistance to endocrine therapy for breast cancer.Targeting breast cancer with CDK inhibitors.Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).

P2860

Q26738985-3AE67166-2FDF-40AE-B0A0-C50565E2B1DB Q26744325-30535E00-E908-410F-A894-58F5CB8CBF37 Q26773500-BDBD2D27-B93B-4A8D-9DCB-F97B99C1B01E Q26777683-38031A51-5598-4CB0-B4A0-134DFEFC995C Q26865888-5CF5BDB4-EFE2-4A40-8B07-FFD8AE23C237 Q26866393-D6C9D210-7F9D-4AF9-8703-992504F17409 Q27001260-20365096-4D5B-4925-8E46-403BD04A6C79 Q27022834-CC0AF0C0-AD66-455A-9AF6-C683D4707917 Q28301066-0CCB65C7-465A-4525-B888-AAC8BDF803B6 Q33617949-5B76E311-478C-47CF-8614-4DF0581DA053 Q33656801-7854C6DF-4376-44DD-94C4-1BBA66430915 Q33816106-1ACA281C-AF76-41F5-8448-C11D053B204B Q34027724-8D3C08A5-BB62-45AC-AC5D-3BFD5DB5F7EC Q34115095-E46D0BB8-445D-4FC0-9151-253256BC70FC Q34147910-F4DA7221-0DDD-43DE-BD63-F45E9349FC5E Q34227791-7BA2C399-C975-4897-B212-C407134A1286 Q34394399-7B6F7F9A-7443-4FBD-9613-0C0F90A12F8F Q34460347-6BE532C9-88FE-4EBD-8E11-46C0728917A9 Q35479617-87BC2632-AF4C-455B-B610-F9778723EDCB Q35530143-00DADB92-980E-4640-A39E-BD8D368250F2 Q35586728-D278AAA8-2144-4FB1-9E1B-2CC03FF81E9F Q35620241-F0348456-7D9C-4354-BE5F-9F4EB514CB13 Q35958082-F63915E7-DFDF-4226-8F1D-6F4F4629B2D4 Q36130090-5CE8DE27-F357-4875-AF94-27D99EB0B387 Q36217351-E6ABADA4-06DD-4BBD-9407-94E4DDB57468 Q36317659-3F151699-AFB0-4E0A-B046-D8E1249F193E Q36420373-CD5EC604-280D-4D57-83F1-475F723BC2B9 Q36604665-D5E317FF-EB05-441B-9DA2-F0F26EEBE4AB Q37012053-44FB3C58-2207-4043-9768-3C9F3B69FB2A Q37234829-7D5D0ECA-5FDF-460E-871F-A2A8BCEEDC7E Q37502364-FBB8340B-F02A-48E8-9CF7-ABD80F333158 Q37584898-DF417A94-CEDB-4A84-AC43-E6CADBBD8B5E Q37632170-D9CB7D01-50D6-40FD-87C6-8629356BA6DC Q37688324-C3B90E31-4D88-4C68-A745-A8199652AFF4 Q37693690-2E2E699A-968E-46C4-BE29-2351C33B35F1 Q38192017-7E040BB2-C134-4F2D-B8B4-11E88A7ACFFE Q38221463-F667191B-F52A-477D-BF66-48AFC7DBE4CE Q38365261-B6C94F41-41E6-4B65-8295-EBEED5DA0D37 Q38374560-E3A980F7-A0E4-420E-847F-DB6B8DC84B7A Q38544813-2C541389-E284-49B9-B8D1-87F3A3ACB958

P2860

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

http://www.wikidata.org/entity/Q30419997

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Therapeutically activating RB: ...... erapy-resistant breast cancer.

@ast

Therapeutically activating RB: ...... erapy-resistant breast cancer.

@en

type

label

Therapeutically activating RB: ...... erapy-resistant breast cancer.

@ast

Therapeutically activating RB: ...... erapy-resistant breast cancer.

@en

prefLabel

Therapeutically activating RB: ...... erapy-resistant breast cancer.

@ast

Therapeutically activating RB: ...... erapy-resistant breast cancer.

@en

P1433

Q30419997-6DB1C72B-BAC9-43B5-988D-59839F3F42A4

P1476

Q30419997-3F07AB36-1513-4592-BC22-8520FE0220E2

P2093

Q30419997-15AA5226-6F3A-4936-8389-96B9D8CA84BD

Q30419997-1E04CBBE-6822-4D72-A4A8-2400A2545ACA

Q30419997-598CF8C7-B32C-4AF6-BB35-FB77029C4049

Q30419997-662D15A8-588A-4B6F-9BAF-ABAC65D84006

Q30419997-90FF0681-AAE4-4C3E-8834-1176DD0E3549

Q30419997-F4C66A8E-D016-4155-8CDE-FC28148FA5BC

P2860

Q30419997-0487FC54-C67C-48E0-87CF-530BBD1DEB07

Q30419997-0576FDFC-0D6B-49DD-BD96-6045B4E9409A

Q30419997-05C4C79A-B37F-4D35-A6BE-B11E0FD3C792

Q30419997-07972CC1-88DC-402E-A11B-9B5C16D1F32E

Q30419997-094329DF-D41D-43B4-89FB-804559884ECF

Q30419997-0DB35E27-1C9A-42CE-A3EE-9420CA538236

Q30419997-15AAAC8D-2AD7-4AAF-AFEE-637CDB2E977C

Q30419997-1BCA9D5F-9504-4700-8ECA-F505AEBCF8AD

Q30419997-2A4D7796-EA9D-417C-B9E9-F37C167A36FA

Q30419997-2D11B682-0FB0-4E16-BCF5-4E822180F28D

P304

Q30419997-116B9E38-A2A8-4723-92D3-080184E5A324

P31

Q30419997-CB36D5CB-879C-446D-954B-E3632E07623D

P356

Q30419997-C927511D-5066-400C-A9BB-BE3DAA580160

P433

Q30419997-E71E6363-BFAB-40A5-BF8C-3BF0C9547DB8

P478

Q30419997-1C46AE22-2D45-4351-B345-6BB3E3EC108D

P50

Q30419997-449A7804-BFC4-4C69-88D6-48D77B4F1425

Q30419997-9C7916E0-C4E4-4ACD-B2FF-AE80AAC0BDF0

P577

Q30419997-A6DE0B4D-D345-4C87-9D1A-66B57E538968

P698

Q30419997-6AE7C799-2F18-42AB-9B8F-0621CE67B2D6

P932

Q30419997-0D108712-CCF1-4A10-A0B8-7E85DFAC2D16

P356

P1433

Endocrine-related cancer

P1476

Therapeutically activating RB: ...... erapy-resistant breast cancer.

@en

P2093

Adam Ertel

http://www.w3.org/2001/XMLSchema#string

Agnieszka K Witkiewicz

http://www.w3.org/2001/XMLSchema#string

C Marcelo Aldaz

http://www.w3.org/2001/XMLSchema#string

Chellappagounder Thangavel

http://www.w3.org/2001/XMLSchema#string

Erik S Knudsen

http://www.w3.org/2001/XMLSchema#string

Jeffry L Dean

http://www.w3.org/2001/XMLSchema#string

P2860

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.

Cyclin D1 in breast cancer

The molecular pathology of cancer

Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model

Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.

P304

333-345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-10-0262

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Karen E Knudsen

P577

2011-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21367843

http://www.w3.org/2001/XMLSchema#string

P932

3624623

http://www.w3.org/2001/XMLSchema#string